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ical devices and pharmacy costs. Reimbursements for patients with declining renal
function were estimated at €4,933 368.9 for monotherapy, €4,521 350.8 for dou-
ble therapy, €4,191 497.9 for triple therapy and €13,768 1106.2 for insulin
therapy. CONCLUSIONS: Overall, ambulatory care costs increase with treatment
escalation and declining renal function amongst T2DM patients. Insulin therapy is
associated with substantial increased costs, related to pharmacy, nursing care and
medical device utilization.
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OBJECTIVES:Hypoglycaemia is a common adverse event associated with the man-
agement of both type 1 and type 2 diabetes. While many hypoglycaemic episodes
can be self-treated, more severe episodes can require emergency treatment and
hospitalisation. The objective of our study was to evaluate the burden of hypogly-
caemia on secondary care costs in England. METHODS: Data captured in Hospital
Episode Statistics (HES)* for the period between 2006 and 2009 was analysed to
estimate the trends in hospital episodes. The associated costs were estimated
using Hospital Resource Group (HRG) tariff prices in England for the respective
years. RESULTS: There were a total of 11,330 inpatient spells assigned an HRG for
hypoglycaemia in 2009, an increase of 17.0% from 2006 when there were 9,682
inpatient spells. In 2006 the average inpatient length of stay was 5.7 days, but by
2009 this figure had risen by 21.1% to 6.9 days. In 2006 the cost of hypoglycaemia
due to hospitalisation was £13.57 million. In 2009 this figure was £16.04 million,
representing an 18.2% increase in cost burden. In 2009 the average inpatient cost
was £1635, up 8.7% from 2006 when the average cost was £1504. Over the four year
period 2006-2009 there were a total of 41,717 inpatient spells due to hypoglycaemia
at a total cost of £58.44 million. CONCLUSIONS: Hypoglycaemia represents a sig-
nificant and increasing burden on hospital care in England. Given current cost
constraints in the NHS, prescribers should seek to use medications that reduce the
risk of hospitalisation due to hypoglycaemia.
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OBJECTIVES: Diabetes affects 3%-5% of total UK population and insulin is the larg-
est drug-class category used to treat the disease. A greater understanding of the
impact of different economic and epidemiological variables on total insulin sales
will help the healthcare system and pharmaceutical industry be more responsive
to demand and cost. METHODS: Generalized least squares regression with period
random effects was used on a pooled yearly data set (2001 to 2010) of variables. The
dependent variable was total yearly sales for insulin. The explanatory variables
included - size of population; incidence and prevalence of diabetes; estimated total
prescription (Rx) for insulin; and employee compensation per capita. The analysis
used yearly pooled, cross-sectional data from IDF and IHS Forecasting Database at
different time points to account for the variation in different variables. The total
population was obtained from OECD. The prevalence and incidence rates were
obtained from IDF for 2001, 2003, 2007 and 2010; average of previous year’s data-
points were used for years in which no data was provided. The main independent
variable was the total yearly prescription rate for insulin, calculated from data
derived from intrinsic Patient Flow Model. RESULTS:A direct correlation was found
between estimated total Rx for insulin, total population, and prevalence rates for
diabetes. The results can be summarized as: For every 1% rise in total estimated Rx
for Insulin and total population there is a 71% and 48% increase in insulin sales,
respectively. CONCLUSIONS: Based on our model, total Rx plays a major role in
determining the total sales for insulin. From a policy perspective, it will support UK
government’s diabetes related initiatives focusing on effective cost management.
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OBJECTIVES: To undertake resource re-allocation for improvements in service and
patient outcomes within a diabetes programme using PBMA. METHODS: UK Na-
tional Health Service organisations have to manage severe budget pressures. If
health outcomes for patients are to be maintained and improved, resources must
be (re)allocated efficiently and some disinvestment is inevitable. PBMA is an ideal
framework for these tasks as it is based on opportunity costs and maximisation of
benefits. The pilot PBMA exercise reported was undertaken in an English PCT in
2010. Data on the inputs and outputs of diabetes care received by patients was
collected and evaluated by a multidisciplinary group of commissioners, healthcare
staff and patient representatives. Through comparison of the data with other PCTs,
and a review of the literature concerning the effectiveness and cost-effectiveness
of current and proposed interventions within the programme, the multidisci-
plinary group identified opportunities for resource reallocation. RESULTS: In com-
parisons, the PCT had near average spending but with poor HbA1c outcomes, use of
glucose blood testing reagents was high - the third most costly prescribed item and
of overall drug spending. Reducing unnecessary spending on these in type II dia-
betes patients freed resource for specialist nurses to coach patients in optimal
diabetes control. CONCLUSIONS: Literature reporting successful implementation
of PBMA is uncommon and factors associated with success are setting, individuals
leading the initiative and buy-in of participants to the process. In this exercise
using detailed financial and outcomes data, implementing PBMA and gaining
buy-in of stakeholders resulted in a successful disinvestment decision, resource
reallocation and re-investment in diabetes services. The next important step is to
use PBMA to make a disinvestment decision alone and improve the process; reduc-
ing the burden of this complex, data-intensive decision-making framework, main-
taining transparency, equity and ethics. This may increase the adoption and suc-
cessful execution of PBMA.
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OBJECTIVES: To analyze the development in the medicines pricing regulation in
Republic of Macedonia during 2005 to 2010 and its impact on medicines
affordability. METHODS: Regulatory analysis of the changes in the medicines
prices regulation for the period 2005 to 2010 was applied. The affordability of the
medicines to the population was explored before the after the new regulation
introduction. Affordability was evaluated through the comparison of the cost of
therapy of the most frequent diseases with the inhabitants wages. For comparison
purposes, the average monthly wages in January 2005 (7.999,00 MKD) and in Janu-
ary 2010 (14.914,00 MKD) were used as announced by the UJP (Public Revenue Office
of Macedonia). The statistical test used was Wilcoxon Matched Pais Test. RESULTS:
The unified medicines prices were established in 2007 based on ex-factory price,
wholesale mark-ups and pharmacy mark-ups. The Health Insurance Fund carried
out the supply of medicines on the Positive list by international tenders until 2005.
The reference pricing was introduced in 2007 and it took into consideration the
Purchasing Parity Power. The statistical analysis of the cost of treatment for se-
lected health conditions compared with the average monthly wages, expressed as
working hours shows that less working hours are needed to purchase medicines
for all clinical conditions in 2010 compared to 2005. There is statistically significant
difference in the working hours needed to purchase medicines between 2010 and
2005 (Wilcoxon Matched Pairs Test: Z  2240, p  0, 0250). The better financial
affordability of medicines in 2010 is a result of partly lower medicines prices, but
predominantly a result of higher monthly wages. CONCLUSIONS: The analysis
reveals the positive impact of medicines price control and reference pricing on
medicines affordability. The number of working hours needed to purchase a month
of treatment decreased.
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OBJECTIVES: To evaluate the association of knowledge and medication adherence
with glycemic control in patients with diabetes mellitus type 2. METHODS: The
research was shaped as a cross-sectional, investigational study. Convenient sam-
pling was done to identify a cohort of 540 diabetic patients attending diabetes clinic
of Hospital Pulau Pinang, Penang, Malaysia. A previously validated knowledge test
and medication adherence scale was used for data collection. Patients’ medical
records were reviewed for haemoglobin A1C (HbA1C) levels and other disease-
related information.RESULTS: Five hundred five patients were included in the final
analysis, with a mean age of 58.15 years (SD9.16) with 50.7% males having mean
HbA1C of 7.94 (SD1.61). Knowledge scores ranged from 0 to 14, with mean scores
of 7.44 (SD3.08). Medication adherence scores ranged from 0 to 8 with mean
scores of 6.11 (SD1.66). HbA1C was found to be significantly lower in patients with
higher level knowledge and higher level of medication adherence (p0.05). Signif-
icant correlations were found between the three variables HbA1C, Knowledge and
adherence (p0.05). Combined therapy, higher diabetes knowledge and higher
medication adherence were statistically predictors of good glycemic control.
CONCLUSIONS: There is a high prevalence of poor glycemic control among pa-
tients in this study. This study revealed that knowledge and adherence are among
the modifiable factors that are associated with better glycemic control.
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OBJECTIVES: To evaluate the medication adherence and general diabetes knowl-
edge among patients with type 2 diabetes and to assess the relationship of knowl-
edge with medication adherence of patients. METHODS: A cross-sectional study
design was conducted among convenience sample of 505 type 2 diabetic outpa-
tients in the Diabetes Clinic of the Penang General Hospital, Penang, Malaysia from
November 2009 to April 2010. Patients with diabetes type 2 were asked to complete
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a short questionnaire about socio-demographic data, adherence (Morisky Medica-
tion Adherence Scale) and knowledge (Michigan Diabetes Knowledge Test) while
medical records were reviewed for diabetes-related data. RESULTS: The mean age
was 58.16 years (SD9.16) with around 50% males. The mean MMAS score of the
patients was 6.11 (SD 1.66) and the total mean score of MDKT was 7.44 (SD3.08).
A significant positive correlation between MMAS and MDKT scores were found (n
505, rs  0.456, p  0.001). A significant association between knowledge levels and
adherence levels was found (p0.05). The correlation coefficient between HbA1C
and total knowledge score was – 0.39 (p 0.001). Higher diabetes knowledge was a
significant predictor of higher medication adherence (OR  1.381, p  0.001).
CONCLUSIONS: Medication adherence is moderately related with diabetes knowl-
edge. Deficiencies in patients’ knowledge may be the greatest barriers to improving
adherence and improvement of patients’ knowledge could result in better medica-
tion adherence.
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OBJECTIVES: To evaluate the general practitioners’ (GPs) reasons for prescribing
pioglitazone 15 or 30 mg and characterise the patients on these doses. METHODS:
An internet-based survey was conducted among 245 UK GPs who selected reasons
for prescribing pioglitazone 15 or 30 mg/day for their patients. Eligible patients
were 18 years at type 2 diabetes mellitus (T2DM) diagnosis and currently on
pioglitazone (15 or 30 mg) with other oral antihyperglycaemic agents for 3
months. GPs provided clinical data for1 patient on each pioglitazone dose. The 29
potential reasons for prescribing the current pioglitazone dose were classified into
4 categories: sufficient glycaemic control, poor tolerability and/or side effects as-
sociated with pioglitazone, comorbidity/polypharmacy, and patient-related
factors.RESULTS:Of the 1456 patients provided by GPs, 739 were on pioglitazone 15
mg and 717 on 30 mg. Compared with the 30-mg group, patients in the 15-mg group
had a shorter duration of T2DM (median 7.3 vs. 8.3 years) and the same median
HbA1c level (7.2%). Collectively, reasons in the sufficient glycaemic control category
were selected most for both groups; however, they were selected more often for 15
than 30 mg (85 vs. 75%, p0.0001). Specifically, new user was selected for 26% on
15 mg and 11% on 30 mg (p0.0001). No significant differences between groups
were seen within the other categories. Overall, 37% of GPs selected reasons related
to poor tolerability and/or side effects, 42% for comorbidity/polypharmacy, and
30% for patient-related factors. GPs indicated they had no plans to change the
current pioglitazone dose for 58% on 15 mg and 66% on 30 mg. CONCLUSIONS: UK
GPs in this study appear comfortable with their current pioglitazone dose choice for
their patients and a majority of GPs planned to have their patients continue on
their current pioglitazone dose in combination therapy.
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OBJECTIVES: To explore the utility of a novel Subgroup Identification Tool (SIT) in
a healthcare database; specifically to identify which patient subgroup would
achieve better outcome from which treatment option.METHODS: For the purposes
of this study, two cohorts of patients with type II diabetes were extracted from the
UK General Practice Research Database. Study patients were 40 years old, were
newly prescribed with antidiabetics Drug A or Drug B, and had at least 6-month
pre-index and 12-month post-index history. The index date was defined as the date
of first prescription for Drug A or Drug B. The outcome was the average HbA1c from
3 months post-index to the end of 12-month follow-up. Subgroups were con-
structed using the SIT, which employs a novel SIDES (subgroup identification based
on differential effect search) methodology. RESULTS: A total of 4824 patients were
identified initiating Drug A and 1007 patients initiating Drug B. Slightly more pa-
tients achieved HbA1c7% for Drug A (46.4%) compared with Drug B (42.6%), trans-
lating to the number needed to treat (NNT) of 26 in favor of Drug A. The SIT iden-
tified a subgroup (male, 71 years old without a prescription for antihypertensives)
where the Drug A patients responded more favorably than Drug B in terms of
achieving HbA1c 7% (NNT 8 in favor of Drug A); and a subgroup (female, low
density cholesterol 120mg/dl with a prescription for angiotensin-converting en-
zyme inhibitors) where the Drug-B patients responded more favorably (NNT 10 in
favor of Drug B). CONCLUSIONS: This study indicates that the SIT can be useful
when applied to healthcare data to identify subgroups that are more likely to
achieve better outcome from one of the two comparative treatment options. The
results from the SIT could be used for hypothesis generation. Validation using
independent data is warranted.
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OBJECTIVES: To validate the recently updated Charlson Comorbidity Index (CCI)
for the prediction of healthcare utilization and to compare its predictive power in
patients with diabetes or asthma.METHODS:Data were retrieved from the Medical
Expenditure Panel Survey (MEPS) Panel 12 (2007-2008) for this retrospective cohort
study. The original CCI (CCI-1) and updated CCI (CCI-2) scores were calculated for
patients who had diabetes or asthma in 2007. Adjusted R2 from linear regression
models were used for the estimation of log-transformed healthcare expenditures
(COST) in 2008. C statistics from logistic regression models were used to compare
the predictive power of the risk of hospitalizations ( 1 admission), risk of emer-
gency department visits ( 1 visit), and high expenditures ( 90th percentile of
COST) in 2008. RESULTS: 833 diabetic patients and 704 asthmatic patients were
included in the study. The diabetes cohort had a mean age of 59.7 years (SD: 15.3),
and 54% were female; the asthma cohort had a mean age of 37.8 years (SD: 23.6),
and 59% were female. In the linear regressions, the CCI-2 explained more variance
in COST in diabetic patients than in asthmatic patients (adjusted R2  17.4% vs.
14.1%), adjusting for demographics. The CCI-2 was a better predictor of high COST
(c  0.881 vs. 0.816) and the risk of hospitalization (c  0.713 vs. 0.682) but a poorer
predictor of the risk for an emergency department visit (c  0.583 vs. 0.653) in the
diabetes cohort than in the asthma cohort. In both cohorts, the CCI-2 (c  0.583 to
0.881) exhibited consistently better predictive power than the CCI-1 (c  0.576 to
0.839). CONCLUSIONS: The predictive power of CCI varies depending on the out-
comes of interest in patients with diabetes or asthma. The updated CCI showed
improved predictive performance compared to the original CCI.
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OBJECTIVES: To develop a method to adjust the medication possession ratio (MPR)
for type 2 diabetes patients who used a vial or pen form of insulin.METHODS:Using
a retrospective analysis of large US health claims data from 2003 to 2008, diabetes
patients who had at least two insulin prescription fills during the pre-index period
were selected. The index date was the date of the first fill of insulin during the
identification period from 2004 to 2007. One year of pre- and post-index continuous
enrollment was required. Patients were excluded from the study if they switched to
another form of insulin during the post-index period or had a diagnosis of gesta-
tional diabetes during the pre- or post-index period. MPR was calculated as a mea-
sure of drug adherence for patients who used vial insulin (&#x0018;Vial
Cohort&#x0019;), and for those who used pen form insulin (’Pen Cohort’). Since
insulin is a multi-dose treatment and is available in several package sizes, tradi-
tional MPR calculation is not suitable for this study. We adjusted the MPR by mul-
tiplying the traditional MPR by (average days between prescription refills/average
days’ supply) for patients in both cohorts. RESULTS: The unadjusted MPR during
the post-index period for patients who used the pen device is lower than for pa-
tients who used a vial (0.55 vs. 0.60, p0.0082). After controlling for baseline patient
characteristics as well as the differences in package size between the pen and vial
insulin using the new calculation method, the adjusted MPR for patients in the ’Pen
Cohort’ was higher than for patients in the ’Vial cohort’ (0.22 vs. 0.13, p0.001).
CONCLUSIONS: After modifying the traditional MPR by adjusting the package size
of the pen or vial insulin device, the adjusted MPR showed that pen insulin users
had a significant advantage in drug adherence over vial users.
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OBJECTIVES: The growing prevalence of diabetes mellitus highlights the conflict
between the burden of disease and sustainability of health care systems, especially
in Central-Eastern European middle income countries. Open access health eco-
nomic models that calculate the effects of health policy programs and public in-
terventions can improve the appropriateness of decisions. Our objective was to
develop a long term economic model for type 2 diabetes and make it available for
public sector decision-makers to support evidence based health policy decisions.
METHODS: The health economic model projects outcomes for selected patient
populations, taking into account baseline patient characteristics, history of com-
plications, changes in physiological parameters over time, diabetes treatment and
management strategies, and screening programs. First section of the model exam-
ines secondary prevention strategies of type 2 diabetes in a decision tree structure.
The second section simulates patients through interconnected Markov sub-models
that replicate important complications of diabetes (ischemic heart disease, reti-
nopathy, hypoglycaemia, nephropathy, neuropathy, foot ulcer, peripherial vascu-
lar disease, stroke and ketoacidosis). Treatment and management strategies are
taken into account when modeling patient pathways. The model includes a wide
range of economic and clinical input data to support adaptability, country- or pro-
vider-specific outcomes and the analysis of different policy and treatment
strategies. RESULTS: In this paper we present the methodological approach, the
model structure, main scientific evidences applied and the choice of policy or treat-
ment strategies that can be examined. CONCLUSIONS: Evidence based health pol-
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